Marie E. Fallon - Mar 31, 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Mar 31, 2023
Transactions value $
-$11,081
Form type
4
Date filed
4/5/2023, 06:38 PM
Previous filing
Mar 24, 2023
Next filing
May 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +13.7K +8.33% 178K Mar 31, 2023 Direct F1
transaction DNA Class A Common Stock Options Exercise +3.75K +2.11% 182K Mar 31, 2023 Direct F2
transaction DNA Class A Common Stock Options Exercise +307 +0.17% 182K Mar 31, 2023 Direct F3, F4
transaction DNA Class A Common Stock Sale -$11.1K -8.73K -4.8% $1.27 173K Apr 3, 2023 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -13.7K -3.55% 371K Mar 31, 2023 Class A Common Stock 13.7K Direct F1
transaction DNA Restricted Stock Units Options Exercise -3.75K -2.08% 176K Mar 31, 2023 Class A Common Stock 3.75K Direct F2, F6
transaction DNA Class B Common Stock Options Exercise -307 -0.6% 50.9K Mar 31, 2023 Class A Common Stock 307 Direct F3, F4, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,684 of the RSUs was satisfied on April 1, 2023, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
F4 Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
F5 Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F6 The RSUs vest in 48 equal monthly installments, which began on April 1, 2023.
F7 Includes shares of Class B Common Stock that are subject to vesting conditions.

Remarks:

Chief Accounting Officer